Skip to content
Review Open access

Nociceptin/Orphanin FQ Peptide (NOP) Receptor Agonists as Novel Analgesics in Pain Medicine

Oct 2026 · Journal of Clinical Medicine · Vol 15, pp. 7942 · 0 citations · 126 references
Medicine

TL;DR

The goal of this narrative literature review was to compile the available data on NOP receptor-targeted analgesics, with a focus on dual NOP/MOP agonists and cebranopadol.

Abstract

Chronic pain is a major cause of disability worldwide, impacting around 20% of adults globally. Conventional mu-opioid peptide (MOP) receptor agonists provide effective analgesia; however, their prolonged use is restricted by severe dose-limiting toxicities such as opioid-induced respiratory depression, analgesic tolerance, hyperalgesia, physical dependence, and addiction. The goal of this narrative literature review was to compile the available data on NOP receptor-targeted analgesics, with a focus on dual NOP/MOP agonists and cebranopadol. The pharmacological mechanisms, preclinical and clinical evidence, safety profile, and potential therapeutic role in pain management were all highlighted. The nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor system has been identified as a new pathway for managing pain through mechanisms that differ from those of classical opioid signaling. The NOP receptor is a Class A G-protein-coupled receptor (GPCR) that preferentially couples to inhibitory G(i/o) proteins. Upon activation, it suppresses adenylyl cyclase activity, lowers intracellular cyclic adenosine monophosphate (cAMP) levels, blocks voltage-gated calcium channels, and activates G-protein-gated inwardly rectifying potassium channels, thereby hyperpolarizing neurons and decreasing excitatory neurotransmitter release. NOP receptors are anatomically distributed throughout the peripheral and central nervous systems, including primary afferent sensory neurons, dorsal root ganglia, spinal dorsal horn, periaqueductal gray, rostral ventromedial medulla, central amygdala, ventral tegmental area, and nucleus accumbens. NOP activation via these pathways offers significant pain relief in acute nociception, as well as in chronic inflammatory and neuropathic pain conditions. Supraspinal activation of NOP within the mesocorticolimbic pathway influences the emotional aspect of pain by reducing corticotropin-releasing factor signaling and decreasing mesolimbic dopamine release. NOP agonism effectively provides analgesia while also attenuating drug reward and reinforcement. The development of pharmaceuticals utilizing NOP agonism has progressed from endogenous peptide analogues to selective non-peptide agonists, and more recently to bifunctional NOP/MOP (dual NMR) agonists, such as the dual NOP/MOP agonist cebranopadol, which has passed Phase I–III clinical testing. There are still significant questions about long-term safety, comparative efficacy, and the interpretation of unpublished or preliminary Phase III results, despite the fact that available clinical trials indicate analgesic efficacy with perhaps decreased respiratory and abuse-related effects. This drug achieves equianalgesic efficacy through potent dual NOP/MOP activation while significantly reducing the risk of respiratory depression and drug-liking. However, clinical translation of NOP receptor agonism is hindered by several challenges, including supraspinal pronociceptive paradoxes, species-specific pharmacology, dose-dependent sedation, and regulatory complexities associated with mixed-mechanism ligands. NOP-targeted therapies represent a promising approach for the development of next-generation, opioid-sparing analgesics in pain medicine.

Read PDF

Similar papers

Review Open access Nov 2026

Cebranopadol: A mixed-efficacy nociceptin/opioid receptor ligand for pain management—pharmacology, clinical evidence, safety, and abuse liability: A narrative review

Pain remains a leading cause of disability worldwide, and the opioid crisis has intensified demand for analgesics that preserve efficacy while reducing respiratory depression, tolerance, dependence, and misuse. Cebranopadol is an investigational spiroindole ligand that binds NOP, MOP, KOP, and DOP receptors with mixed...

M. Afighor, O. Adhekegba, C. E. Ezerioha et al. · 0 citations
Review Nov 2026

Neurotensin Signaling in Analgesia: Receptor Mechanisms, Targeted Drug Development, and Therapeutic Prospects for Pain and Comorbid Depression.

Opioids are effective for severe pain but are limited by adverse effects and the risk of opioid use disorder (OUD), while non-opioid analgesics may provide insufficient relief. Neurotensin (NT), an endogenous neuropeptide, has attracted interest as a potential analgesic, with encouraging findings mainly from preclinica...

Fei Xu, N. Sudhan, Ke Peng et al. · 0 citations
Open access Nov 2026

Design, Synthesis, and Pharmacological Characterization of Novel Kappa Opioid Receptor Agonists via Isosteric Replacement Strategy for Inflammatory Pain

Pharmacokinetic studies identified compound 10 as a P-glycoprotein substrate with limited brain exposure, consistent with a CNS-sparing profile and preferentially peripheral activity, and was identified as a KOR-mediated antinociception candidate.

Ahmed M. Reda, Logan T. Neel, Celsey M. St. Onge et al. · 0 citations
Review Open access Oct 2026

The NMDA receptor in opioid-induced hyperalgesia: From neuroplasticity to perioperative prevention- Narrative review

Importance. Opioid-induced hyperalgesia (OIH) is a paradoxical increase in nociceptive sensitivity attributable to opioid exposure. In the perioperative period, recognition is difficult because pain from surgical injury, inadequate analgesia, pharmacological tolerance, and acute withdrawal produce overlapping phenotype...

Gloria Anabel Ortiz Cruz, Oscar Leonardo Castillo Cueva, Darlyn Dayana Arciniega Guerrero et al. · 0 citations
Review Open access Sep 2026

Opioid Peptide Hybrids as Multifunctional Analgesic Ligands: Emphasis on Intracellular Signaling

Opioid peptide hybrids are multifunctional molecules in which an opioid pharmacophore is covalently integrated with a second opioid or non-opioid pharmacophore within a single molecular entity. Their development is driven by a major challenge in analgesic pharmacotherapy: although μ-opioid receptor (MOR) agonists remai...

Igor Cecherz, Jakub Waśkiewicz, Alicja Dudek et al. · 0 citations
Review Open access Oct 2026

Oliceridine for acute pain management: pharmacology, clinical efficacy, safety, and future perspectives: a narrative review.

Opioids are a cornerstone in the management of moderate-to-severe acute pain; however, their clinical utility is limited by well-recognized challenges, including respiratory depression, gastrointestinal (GI) dysfunction, and the potential for misuse and abuse. Oliceridine is a novel μ-opioid receptor agonist with G-pro...

Min Kyoung Kim, Hyun Kang · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.